Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Accenture
UBS
Cantor Fitzgerald
Teva
Boehringer Ingelheim
QuintilesIMS
Deloitte
Fish and Richardson
McKesson

Generated: January 18, 2018

DrugPatentWatch Database Preview

Tesamorelin acetate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for tesamorelin acetate and what is the scope of tesamorelin acetate patent protection?

Tesamorelin acetate
is the generic ingredient in one branded drug marketed by Theratechnologies and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tesamorelin acetate has forty-four patent family members in sixteen countries.

Two suppliers are listed for this compound.
Summary for tesamorelin acetate
International Patents:44
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 1
Clinical Trials: 965
Drug Prices:see low prices
DailyMed Link:tesamorelin acetate at DailyMed

US Patents and Regulatory Information for tesamorelin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for tesamorelin acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 ➤ Subscribe ➤ Subscribe
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for tesamorelin acetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,435,945 GH secretagogues and uses thereof ➤ Subscribe
5,939,386 Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency ➤ Subscribe
6,020,311 GRF analogs with increased biological potency ➤ Subscribe
8,481,489 GH secretagogues and uses thereof ➤ Subscribe
8,314,066 GH secretagogues and uses thereof ➤ Subscribe
6,458,764 GRF analogs with increased biological potency ➤ Subscribe
6,696,063 Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for tesamorelin acetate

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Baxter
Fuji
Cantor Fitzgerald
Accenture
US Department of Justice
McKesson
Covington
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot